Cargando…
Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals
BACKGROUND: Predicting progression to clinical arthritis in individuals at-risk of developing rheumatoid arthritis is a prerequisite to developing stratification groups for prevention strategies. Selecting accurate predictive criteria is the critical step to define the population at-risk. While posi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764647/ https://www.ncbi.nlm.nih.gov/pubmed/36535711 http://dx.doi.org/10.1136/rmdopen-2022-002512 |
_version_ | 1784853316280254464 |
---|---|
author | Ponchel, Frederique Duquenne, Laurence Xie, Xuanxiao Corscadden, Diane Shuweihdi, Farag Mankia, K Trouw, L A Emery, Paul |
author_facet | Ponchel, Frederique Duquenne, Laurence Xie, Xuanxiao Corscadden, Diane Shuweihdi, Farag Mankia, K Trouw, L A Emery, Paul |
author_sort | Ponchel, Frederique |
collection | PubMed |
description | BACKGROUND: Predicting progression to clinical arthritis in individuals at-risk of developing rheumatoid arthritis is a prerequisite to developing stratification groups for prevention strategies. Selecting accurate predictive criteria is the critical step to define the population at-risk. While positivity for anti-citrullinated protein antibodies (ACPA) remains the main recruitment biomarker, positivity for other autoantibodies (AutoAbs) identified before the onset of symptoms, may provide additional predictive accuracy for stratification. OBJECTIVE: To perform a multiple AutoAbs analysis for both the prediction and the time of progression to inflammatory arthritis (IA). METHODS: 392 individuals were recruited based on a new musculoskeletal complaint and positivity for ACPA or rheumatoid factor (RF). ELISAs were performed for ACPA, RF, anti-nuclear Ab, anti-carbamylated protein (anti-CarP) and anti-collagen AutoAbs. Logistic and COX regression were used for analysis. RESULTS: Progression to IA was observed in 125/392 (32%) of cases, of which 78 progressed within 12 months. The AutoAbs ACPA, RF, anti-CarP were individually associated with progression (p<0.0001) and improved prediction when combined with demographic/clinical data (Accuracy >77%; area under the curve (AUC) >0.789), compared with prediction using only demographic/clinical data (72.9%, AUC=0.760). Multiple AutoAbs testing provided added value, with +6.4% accuracy for number of positive AutoAbs (AUC=0.852); +5.4% accuracy for AutoAbs levels (ACPA/anti-CarP, AUC=0.832); and +6.2% accuracy for risk-groups based on high/low levels (ACPA/RF/anti-CarP, AUC=0.837). Time to imminent progression was best predicted using ACPA/anti-CarP levels (AUC=0.779), while the number of positive AutoAbs was/status/risk were as good (AUC=0.778). CONCLUSION: We confirm added value of multiple AutoAbs testing for identifying progressors to clinical disease, allowing more specific stratification for intervention studies. |
format | Online Article Text |
id | pubmed-9764647 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-97646472022-12-21 Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals Ponchel, Frederique Duquenne, Laurence Xie, Xuanxiao Corscadden, Diane Shuweihdi, Farag Mankia, K Trouw, L A Emery, Paul RMD Open Rheumatoid Arthritis BACKGROUND: Predicting progression to clinical arthritis in individuals at-risk of developing rheumatoid arthritis is a prerequisite to developing stratification groups for prevention strategies. Selecting accurate predictive criteria is the critical step to define the population at-risk. While positivity for anti-citrullinated protein antibodies (ACPA) remains the main recruitment biomarker, positivity for other autoantibodies (AutoAbs) identified before the onset of symptoms, may provide additional predictive accuracy for stratification. OBJECTIVE: To perform a multiple AutoAbs analysis for both the prediction and the time of progression to inflammatory arthritis (IA). METHODS: 392 individuals were recruited based on a new musculoskeletal complaint and positivity for ACPA or rheumatoid factor (RF). ELISAs were performed for ACPA, RF, anti-nuclear Ab, anti-carbamylated protein (anti-CarP) and anti-collagen AutoAbs. Logistic and COX regression were used for analysis. RESULTS: Progression to IA was observed in 125/392 (32%) of cases, of which 78 progressed within 12 months. The AutoAbs ACPA, RF, anti-CarP were individually associated with progression (p<0.0001) and improved prediction when combined with demographic/clinical data (Accuracy >77%; area under the curve (AUC) >0.789), compared with prediction using only demographic/clinical data (72.9%, AUC=0.760). Multiple AutoAbs testing provided added value, with +6.4% accuracy for number of positive AutoAbs (AUC=0.852); +5.4% accuracy for AutoAbs levels (ACPA/anti-CarP, AUC=0.832); and +6.2% accuracy for risk-groups based on high/low levels (ACPA/RF/anti-CarP, AUC=0.837). Time to imminent progression was best predicted using ACPA/anti-CarP levels (AUC=0.779), while the number of positive AutoAbs was/status/risk were as good (AUC=0.778). CONCLUSION: We confirm added value of multiple AutoAbs testing for identifying progressors to clinical disease, allowing more specific stratification for intervention studies. BMJ Publishing Group 2022-12-19 /pmc/articles/PMC9764647/ /pubmed/36535711 http://dx.doi.org/10.1136/rmdopen-2022-002512 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Rheumatoid Arthritis Ponchel, Frederique Duquenne, Laurence Xie, Xuanxiao Corscadden, Diane Shuweihdi, Farag Mankia, K Trouw, L A Emery, Paul Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals |
title | Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals |
title_full | Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals |
title_fullStr | Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals |
title_full_unstemmed | Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals |
title_short | Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals |
title_sort | added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals |
topic | Rheumatoid Arthritis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764647/ https://www.ncbi.nlm.nih.gov/pubmed/36535711 http://dx.doi.org/10.1136/rmdopen-2022-002512 |
work_keys_str_mv | AT ponchelfrederique addedvalueofmultipleautoantibodytestingforpredictingprogressiontoinflammatoryarthritisinatriskindividuals AT duquennelaurence addedvalueofmultipleautoantibodytestingforpredictingprogressiontoinflammatoryarthritisinatriskindividuals AT xiexuanxiao addedvalueofmultipleautoantibodytestingforpredictingprogressiontoinflammatoryarthritisinatriskindividuals AT corscaddendiane addedvalueofmultipleautoantibodytestingforpredictingprogressiontoinflammatoryarthritisinatriskindividuals AT shuweihdifarag addedvalueofmultipleautoantibodytestingforpredictingprogressiontoinflammatoryarthritisinatriskindividuals AT mankiak addedvalueofmultipleautoantibodytestingforpredictingprogressiontoinflammatoryarthritisinatriskindividuals AT trouwla addedvalueofmultipleautoantibodytestingforpredictingprogressiontoinflammatoryarthritisinatriskindividuals AT emerypaul addedvalueofmultipleautoantibodytestingforpredictingprogressiontoinflammatoryarthritisinatriskindividuals |